Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

Clinical Therapeutics

Volumn 26, Issue 5, 2004, Pages 704-714

  Postier, Russell G ^a   Green, Stephen L ^b   Klein, Stanley R ^c   Ellis Grosse, E J ^d   Loh, Evan ^d  

^a University of Oklahoma Medical Center   (United States)

^b Hampton Roads Medical Specialists   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d PFIZER INC   (United States)

Author keywords

Antimicrobial resistance; Glycylcycline; Skin and skin structure infection; Tigecycline

Indexed keywords

ANTIBIOTIC AGENT; TIGECYCLINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SENSITIVITY; DRUG TOLERABILITY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FEMALE; FEVER; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PENICILLIN RESISTANCE; PHASE 2 CLINICAL TRIAL; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME; VOMITING;

EID: 2942571341     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90070-7     Document Type: Article

References (17)

1. CDC (Centers for Disease Control and Prevention) Web site. Background on antibiotic resistance. Available at: http://www.cdc.gov/drugresistance/ community/. Accessed May 16, 2003.
2. Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett. 1999;9:1459-1462.
3. Chopra I. Glycylcyclines: Third-generation tetracycline antibiotics. Curr Opin Pharmacol. 2001;1:464-469.
4. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy. 2000;20;S219-S223; discussion, S224-S228.
5. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother. 2003;47:400-404.
6. Petersen PJ, Weiss WJ, Labthavikul P, Bradford PA. The post-antibiotic effect and time-kill kinetics of the glycylcyclines, GAR-936 (TBG-MINO and PAM-MINO). In: Programs and Abstracts of the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif. 1998. Abstract F-132.
7. Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother. 1999;43:738-744.
8. Lefort A, Lafaurie M, Saleh-Mghir A, et al. Activity and diffusion of GAR 936 (GAR) in experimental enterococcal endocarditis. In: Programs and Abstracts of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. 1999:39. Abstract 1103. Available at: http://asmusa.org/memonly/abstracts/AbstractView. asp?AbstractID=1103. Accessed July 31, 2003.
9. Muralidharan G, Getsy J, Mayer P, et al. Pharmacokinetics (PK), safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. In: Programs and Abstracts of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. 1999. Abstract 416. Available at: http://www.asmusa.org/memonly/ abstracts/AbstractView.asp?AbstractID=1094. Accessed September 23, 2003.
10. Sesoko S, Umemura K, Nakashima M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males. In: Programs and Abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, Calif. 2002:42. Abstract A-1403. Available at: http://www.asmusa.org/memonly/abstracts/AbstractView.asp? AbstractID=70509. Accessed September 16, 2003.
11. NCCLS. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard - Fifth Edition. Wayne, Pa: NCCLS; 2001. NCCLS document M11-A5.
12. NCCLS. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - Eighth Edition. Wayne, Pa: NCCLS; 2003. NCCLS document M2-A8.
13. NCCLS. Methods for Dilution Antimicrobial Susceptibility Tests for Microbes that Grow Aerobically; Approved Standard - Sixth Edition. Wayne, Pa: NCCLS; 2003. NCCLS document M7-A6.
14. Gibaldi M, Perrier D, eds. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker; 1982.
15. Muralidharan G, Mojaverian P, Micalizzi M, et al. The effects of age and gender on the pharmacokinetics, safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. In: Programs and Abstracts of the 40th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Ontario, Canada. 2000:40. Abstract 502. Available at: http://www.asmusa.org/memonly/abstracts/AbstractView.asp? AbstractID=82056. Accessed September 23, 2003.
16. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: A randomized, open-label trial. Clin Infect Dis. 2002;35: 381-389.
17. Siami G, Christou N, Eiseman I, et al. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother. 2001;45:525-531.